OAO. V. Avdei

O. V. Avdei

*This is an algorithmically generated author record based on publicly available information.

O. V. Avdei has a total of 24 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    A rare case of early-onset neonatal sepsis caused by Proteus mirabilis in the first infant of tetrachorionic triamniotic triplets

    by A. L. Karpova, A. V. Mostovoi, O. V. Avdei, E. A. Dudkina, S. P. Zagdai, L. A. Anikeeva, A. P. Khoteeva, O. E. Orlova, N. Yu. Karpov

    Early-onset neonatal sepsis (EОNS) is one of the most severe diseases of the neonatal period and is often coupled to extremely unfavorable outcomes. In many ways, the severity of the condition and the results of newborn nursing depend on the etiology of the bacterial process. The major EОNS pathogens are traditionally considered to be Streptococcus group B and E. coli, much less common are other Gram-negative bacteria including casuistic cases caused by caused by Proteus mirabilis (P. mirabilis). The article provides a review on the P. mirabilis role in developing neonatal sepsis with pathogen-specific disease course and outcomes. In addition, we describe a clinical case of P. mirabilis-caused EОNS not only primarily characterized by the rarity of its causative agent, but also that it proceeded with a more favorable brain damage in contrast to similar cases described worldwide and because the neonatal EОNS developed in one of triplets, with two other babies being asymptomatic despite that P. mirabilis was also detected.


  • Open Access

    Early neonatal sepsis in COVID-19 era

    by A. L. Karpova, A. V. Mostovoi, E. А. Dudkina, O. V. Avdei, N. Yu. Karpov

    Introduction. Early-onset neonatal sepsis (EONS) remains the leading cause of serious mobility and mortality worldwide. At the present time, the impact of the COVID-19 pandemic on the incidence of other infections is of particular interest. Aim: to conduct a comparative analysis of the features of the course of EONS in newborns before the COVID-19 pandemic (2018) and during the COVID-19 pandemic (2021). Materials and Мethods. A retrospective cohort single-center continuous study included 73 newborns born and hospitalized in the Regional Kaluga Perinatal Center (PC) based on Kaluga Regional Clinical Hospital. The data for the period of stay in the PC from January to October 2018 and the same period in 2021 were analyzed and compared. Newborns were divided into two groups: group 1 (n = 26) – in 2018, and group 2 (n = 47) – in 2021. The following parameters of EONS severity were selected: the need for the use of norepinephrine, surfactant and fresh-frozen plasma (FFP). Results. The incidence of EONS in 2021 (n = 47) was significantly higher than in 2018 (n = 26): odds ratio (OR) = 3.27; 95 % confidence interval (CI) = 1.57–6.40; p = 0,001. Gestational age and Apgar score at the 1st and 5th minutes were significantly higher in group 1 than in group 2: 36.2 [33.3; 38.0] weeks vs. 33.3 [28.5; 36.1] weeks (p = 0.016); 7.0 [5.0; 7.0] vs. 5.0 [3.0; 7.0] (p = 0.019) and 9.0 [6.8; 8.0] vs. 6.0 [5.0; 8.0] (p = 0.012), respectively. Newborns with EONS in 2021 compared with 2018 showed a significant increase in norepinephrine administration of (42/47 vs. 16/26 newborns, respectively; OR = 5.25; 95 % CI = 1.58–17.44; p = 0.007), FFP transfusions (47/47 vs. 19/26 newborns, respectively; OR = 36.54; 95 % CI = 2.05–649.84; p < 0.001) and surfactant therapy (32/47 vs. 7/26 newborns, respectively; OR = 5.79; 95 % CI = 2.04–16.45; p = 0.001). Mortality among patients with EONS in 2021 compared to 2018 was significantly higher: 13/47 (21.3 %) vs. 2/26 (7.7 %) newborns, respectively (OR = 9.56; 95 % CI = 1.22–74.96; p = 0.014). Conclusion. Among the newborns of the Kaluga region there is a significant rise in the incidence and mortality of EONS on the background of the COVID-19 pandemic. In 2021 there is a significant increase in the need for surfactant administration, use of vasopressors, and transfusion of FFP in infants with EONS.


  • MORBIDITY AND PREDICTORS OF LETHAL OUTCOME IN PREMATURE INFANTS WHO RECEIVED PORACTANT ALPHA WITH GESTATION AGE OF LESS THAN 32 WEEKS

    by A.V. Mostovoi, A.L. Karpova, N.R. Kharitonova, O.V. Avdei, M.A. Kovaleva, Yaroslavl Yaroslavl Oblast Regional Perinatal Center, A.S. Petrova, Balashikha Moscow Oblast Regional Perinatal Center, M.V. Kondratyev, I.I. Mebelova, et al.

    The aim of the study – to analyze the morbidity and search for predictors of death in premature infants with a gestational age (GA) of 32 weeks or less, born in perinatal centers and received Poractant alfa (PA) in the treatment of respiratory distress syndrome (RDS), in order to improve the quality of medical care for premature babies. Materials and methods of research: a multicenter prospective open-label non-randomized continuous comparative study was conducted in five perinatal centers from 2020 to 2021. A total of 264 patients, and inclusion criteria: GA less than 32 weeks, the need for PA replacement therapy in the first minutes of life, the first dose of PA – 200 mg/kg, the second dose of PA – 100 mg/kg, strict adherence to the study protocol. Children who did not require PA therapy in the delivery room, who received other types of surfactants, as well as those with congenital malformations, genetic and/or chromosomal abnormalities, early neonatal sepsis, and deviations from the study protocol were excluded. Children were divided into 3 groups: group 1 (200 children) – invasive PA (ETT), group 2 (19 children) – PA injection by INSURE method, group 3 (45 children) – PA injection by LISA method. Results: the median birth weight of all 264 children was 1090.0 g, GA – 28.0 weeks. The median age of the first PA injection is 10.0 [10.0; 10.0] min of life. PA was reintroduced in 20.1% (53/264) of children, invasive mechanical ventilation (IV) was required in 82.6% (218/264) of cases, high-frequency oscillatory mechanical ventilation (HFOV) – in 24.0% (59/264 ). The incidence of bronchopulmonary dysplasia was 37.5% (99/264) of cases and prevailed in the ETT group in comparison with LISA (43.0% versus 27.0%, respectively, p=0.043) and INSURE (43.0% versus 5.0 %, p=0.001). Predictors of death were low gestational age and birth weight, surgical stage of necrotizing enterocolitis, hemodynamically significant patent ductus arteriosus, grade III intraventricular hemorrhage, and pulmonary hemorrhage. The development of the latter in the first 72 hours of life increases the risk of death by 19.7 times. Conclusions: minimally invasive administration of PA by INSURE and LISA methods associated with reduce of morbidity and improves outcomes in premature infants who less than 32 weeks of GA. Pulmonary hemorrhage was the most dangerous among the predictors of death, increasing the risk of death by almost 20 times.